MedTrace Logo

MTX Discontinuation and Vaccine Response

NCT02748785 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 277

Last updated 2018-10-04

Study results available
· View outcomes & findings →

Summary

To investigate whether a short term discontinuation of methotrexate (MTX) will improve the vaccination efficacy to seasonal influenza vaccination without deteriorating RA disease activity in a randomized clinical trial.

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

Methotrexate

Methotrexate will be continued

BIOLOGICAL

Seasonal Influenza vaccine

all subjects will be vaccinated with a seasonal influenza vaccine

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02748785 on ClinicalTrials.gov